Phase 2 Ovarian Cancer Trial, By Invitation
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person has a confirmed diagnosis of a specific type of ovarian, primary peritoneal, or fallopian tube cancer — including high-grade serous, endometrioid, carcinosarcoma, mixed mullerian with a high-grade serous component, clear cell, or low-grade serous types (only up to 8 people with clear cell carcinoma will be included, and mucinous carcinoma is not included).
- The person has received 2 previous rounds of platinum-based chemotherapy, and their cancer was considered to be responding well to the second-to-last round (meaning there was more than 6 months between finishing that treatment and the cancer getting worse).
- The person's cancer responded (fully or partially) to the most recent platinum-based chemotherapy, is still responding, and the person is enrolled in the study within 8 weeks of finishing that treatment.
- The person is able to provide a freshly taken tissue sample (biopsy) from a tumour for testing before joining the study.
- The person is female, at least 20 years old, and is generally well enough to carry out normal daily activities with little or no difficulty (confirm with trial site for exact performance level required).
- The person's blood counts and organ function fall within acceptable ranges, including: sufficient white blood cells, platelets, and haemoglobin levels; kidneys, liver, and blood clotting functioning within required limits (confirm with trial site for exact values).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- The person has a mucinous, germ cell, or borderline ovarian tumour.
- The person has a known or suspected harmful mutation in the BRCA1 or BRCA2 genes (either inherited or developed over time).
- The person has a history of lung inflammation (not caused by infection) that needed steroid treatment, or currently has lung inflammation.
- The person has, or shows signs of having, myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML), which are blood and bone marrow conditions.
- The person has another cancer that is still growing or has needed active treatment within the past 3 years.
- The person has active cancer that has spread to the brain or spinal cord lining.
- The person has a known history of active tuberculosis (TB).
- The person has a known history of active Hepatitis B or active Hepatitis C infection.
- The person has uncontrolled high blood pressure, defined as readings above 140/90 mmHg on two separate measurements taken at least 1 hour apart.
- The person has had significant bleeding — including coughing up blood or active gastrointestinal bleeding — within the 6 months before joining the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
progression-free survival(6 months PFS rate)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.